BCDx Monitoring
Bladder Cancer — Recurrence Monitoring (Active Surveillance)
Clinical ValidationIn development with partners
Key Facts
Indication
Bladder Cancer — Recurrence Monitoring (Active Surveillance)
Phase
Clinical Validation
Status
In development with partners
Company
About Early Is Good
Early Is Good is redefining cancer diagnostics by addressing the critical blind spot of incomplete biological information. Their proprietary platform integrates three biological dimensions—DNA, RNA, and Proteins—from a single sample with attomolar sensitivity, eliminating the need for extraction or amplification. The company is advancing a pipeline of liquid biopsy tests, has secured significant seed funding and an NIH grant, and is collaborating with leading academic institutions to validate and commercialize its tests, beginning with applications in urologic oncology.
View full company profile